Invesco Ltd. Myovant Sciences Ltd. Transaction History

Invesco Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$11.6 - $20.44 $2.34 Million - $4.13 Million	202,080 New	202,080 $3.63 Million
Q1 2022 May 16, 2022	SELL	$11.38 - $16.4 $299,771 - $432,008	-26,342 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$14.31 - $23.87 $376,954 - $628,783	26,342 New	26,342 $410,000
Q3 2021 Nov 15, 2021	SELL	$18.94 - $26.99 $448,688 - $639,393	-23,690 Closed	0 $0
Q2 2021 Aug 17, 2021	BUY	$17.07 - $24.56 $42,162 - $60,663	2,470 Added 11.64%	23,690 $540,000
Q1 2021 May 17, 2021	BUY	$20.46 - $25.18 $434,161 - $534,319	21,220 New	21,220 $437,000
Q2 2019 Aug 14, 2019	SELL	$8.69 - $25.0 $335,720 - $965,825	-38,633 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$16.83 - $24.45 $650,193 - $944,576	38,633 New	38,633 $922,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.